Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Cohort Prospective Study to Evaluate Immunogenicity of Epodion® (Biosimilar Epoetin-α) in Anemia Associated with Chronic Kidney Disease (CKD) Patients

ACTA MEDICA INDONESIANA · Vol. 54 No. 3 (2022)

ISSN
2338-2732, 0125-9326
Terbit
2022-09-24
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Background: Anemia due to chronic kidney disease (CKD) is often associated with decreased erythropoietin (EPO) levels in the blood. Treatments available are improving blood iron levels and administration of exogenous EPO (rhEPO). This study aims to assess the safety and immunogenicity of Epodion, a biosimilar rhEPO product, in haemodialysis patients with CKD-associated anaemia in three Indonesian hospitals. Methods: This prospective, open label, single arm, and multicenter study enrolled patients with anemia associated with CKD under hemodialysis treatment. Patient eligibility was assessed within the 4-week screening period. Blood samples for determination of erythropoietin antibody (Anti-Drug Antibody) were taken at week-0, 24, and 52 using a validated and highly sensitive bridging ELISA method. Evaluation of Neutralizing Antibody (NAb) was carried out to confirm the impact of the antibody to pharmacological activity (e.g., antibody-mediated PRCA) when the ADA detection of patients was positive after screening and confirmatory assay. Results: Results from all tested patients show that Epodion could maintain hemoglobin and hematocrit levels. ADA detection using ELISA assay yielded negative results for all plasma samples of week-24 and week-52, so the evaluation of NAb was not carried out. No adverse events were considered relevant to tested product. Conclusion: This study proves no immunogenic effect of Epodion on stimulating immune system’s antibodies in Indonesian patients with CKD-associated anemia.

Kata kunci

Jaringan kolaborasi para penulis

15 penulis · 45 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Pringgodigdo NugrohoAfiliasi tidak diketahui2
Lucky Aziza BawazierAfiliasi tidak diketahui1
Kuntjoro HarimurtiAfiliasi tidak diketahui1
Aida LydiaAfiliasi tidak diketahui1
Hamzah ShatriAfiliasi tidak diketahui1
Irsan HasanAfiliasi tidak diketahui1
Ikhwan RinaldiAfiliasi tidak diketahui1
Purwita Wijaya LaksmiAfiliasi tidak diketahui1
Maruhum Bonar H MarbunAfiliasi tidak diketahui1
Ria JauwerissaAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Cohort Prospective Study to Evaluate Immunogenicity  of Epodion® (Biosimilar Epoetin-α) in Anemia  Associated with Chronic Kidney Disease (CKD) Patients</dc:title>
	<dc:creator>Angginy, Nova</dc:creator>
	<dc:creator>Suh, Chang Woo</dc:creator>
	<dc:creator>Jonny, Jonny</dc:creator>
	<dc:creator>Mahnulia, Nuly Juariah</dc:creator>
	<dc:creator>Suhardjono, Suhardjono</dc:creator>
	<dc:subject xml:lang="en-US">Anemia</dc:subject>
	<dc:subject xml:lang="en-US">anti-drug antibody</dc:subject>
	<dc:subject xml:lang="en-US">anti-rhEPO</dc:subject>
	<dc:subject xml:lang="en-US">chronic kidney disease</dc:subject>
	<dc:subject xml:lang="en-US">erythropoietin</dc:subject>
	<dc:description xml:lang="en-US">Background: Anemia due to chronic kidney disease (CKD) is often associated with decreased erythropoietin (EPO) levels in the blood. Treatments available are improving blood iron levels and administration of exogenous EPO (rhEPO). This study aims to assess the safety and immunogenicity of Epodion, a biosimilar rhEPO product, in haemodialysis patients with CKD-associated anaemia in three Indonesian hospitals. Methods: This prospective, open label, single arm, and multicenter study enrolled patients with anemia associated with CKD under hemodialysis treatment. Patient eligibility was assessed within the 4-week screening period. Blood samples for determination of erythropoietin antibody (Anti-Drug Antibody) were taken at week-0, 24, and 52 using a validated and highly sensitive bridging ELISA method. Evaluation of Neutralizing Antibody (NAb) was carried out to confirm the impact of the antibody to pharmacological activity (e.g., antibody-mediated PRCA) when the ADA detection of patients was positive after screening and confirmatory assay. Results: Results from all tested patients show that Epodion could maintain hemoglobin and hematocrit levels. ADA detection using ELISA assay yielded negative results for all plasma samples of week-24 and week-52, so the evaluation of NAb was not carried out. No adverse events were considered relevant to tested product. Conclusion: This study proves no immunogenic effect of Epodion on stimulating immune system’s antibodies in Indonesian patients with CKD-associated anemia.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2022-09-24</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US">prospective, open label, single arm, and multicenter study</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/1946</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 54 No. 3 (2022): Acta Medica Indonesiana; 397</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/1946/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2022 Nova Angginy, Chang Woo Suh, Jonny Jonny, Nuly Juariah Mahnulia, Suhardjono Suhardjono</dc:rights>
</oai_dc:dc>